Engineers Gate Manager’s Akebia Therapeutics AKBA Stock Holding History

Engineers Gate Manager’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$111K	Buy	+79,587	New	+$109K	﹤0.01%	2005
2025 Q4	–	Sell	-46,345	Closed	-$127K	–	2066
2025 Q3	$127K	Buy	+46,345	New	+$154K	﹤0.01%	1982
2022 Q1	–	Sell	-80,072	Closed	-$181K	–	1809
2021 Q4	$181K	Buy	+80,072	New	+$218K	0.01%	1688
2021 Q1	–	Sell	-44,300	Closed	-$124K	–	1780
2020 Q4	$124K	Sell	44,300 -147,700	-77%	-$431K	0.01%	1562
2020 Q3	$482K	Buy	+192,000	New	+$1.68M	0.02%	1015

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Engineers Gate Manager's AKBA Position: Q1 2026 in Review

Engineers Gate Manager opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 79,587 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #2005 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in AKBA as recently as Q3 2025.

Engineers Gate Manager first reported a position in AKBA in Q3 2020 and has held it in 5 quarters since. The position peaked at $482K in Q3 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Engineers Gate Manager held 79,587 shares of Akebia Therapeutics worth $111K as of Q1 2026.
Akebia Therapeutics was a new Engineers Gate Manager position in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q1 2026, its #2005 holding.
Engineers Gate Manager first reported a position in Akebia Therapeutics in Q3 2020 and has held it in 5 quarters since.
Engineers Gate Manager's Akebia Therapeutics position peaked at $482K in Q3 2020.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.